Andean Precious Metals reported its Q2 2026 financial results, highlighting a strategic deferral of silver and gold sales that increased finished inventory to $37.6 million, with subsequent sales expected to boost Q3 revenue. The company saw a 4% increase in gold equivalent production year-over-year and a 15% rise year-to-date, driven by strong performance at San Bartolome. Despite lower reported revenue due to sales deferral, higher realized prices and operational efficiency support full-year guidance. Andean also strengthened its balance sheet, reduced debt, and advanced corporate initiatives including a planned NYSE listing and board expansion, positioning for future growth.
Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...
Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...
